US · Healthcare · Biotechnology
EPS came in at -0.09 against a street estimate of -0.06 — a miss of 50.0%.
Analysts rate Arcutis Biotherapeutics Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $34.62.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.86% |
| Frazier Life Sciences Management, L.P. | 7.89% |
| BlackRock Inc | 7.36% |
| Rubric Capital Management LP | 6.61% |
| State Street Corp | 5.03% |
| Polar Capital Holdings PLC | 4.53% |
| Jennison Associates LLC | 3.98% |
| Vanguard Capital Management, LLC | 3.89% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 | 2026-07-16 |
| Shareholder vote results · Q2 2026 | 2026-06-09 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Current report · Q2 2026 | 2026-05-06 |
| Proxy statement · Q2 2026 | 2026-04-21 |
| Annual report FY2025 | 2026-02-25 |
| Results announced · Q1 2026 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-10-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Arcutis Biotherapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.